Prestige Consumer Healthcare Inc. PBH
46.61
0.96
2.10%
as of 25 Sep
- Market cap
- $2.2B
- P/E
- 13.0×
Follow PBH
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
13.17 | 15.04 | 16.19 | 15.37 |
+8 more quarters Free account |
P/S ratio |
2.03 | 2.64 | 2.68 | 2.75 | |
P/FCF ratio |
9.53 | 11.65 | 11.05 | 11.98 | |
P/Operating CF |
31.69 | 67.04 | 37.73 | 53.22 | |
P/B ratio |
1.17 | 1.52 | 1.61 | 1.68 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.79 | 3.52 | 3.58 | 3.57 | |
EV/EBITDA |
12.92 | 11.18 | 11.16 | 10.92 | |
EV/Operating CF |
16.80 | 14.87 | 14.29 | 15.04 | |
EV/FCF |
17.80 | 15.54 | 14.80 | 15.51 | |
Quick Ratio |
1.80 | 2.12 | 1.81 | 2.36 | |
Current Ratio |
3.23 | 3.57 | 3.11 | 3.70 | |
Net Debt/EBITDA |
31.52 | 11.25 | 10.93 | 10.18 | |
Debt/Assets |
44.54% | 28.96% | 30.11% | 29.41% | |
Debt/Equity |
1.06 | 0.54 | 0.58 | 0.55 | |
Asset Turnover |
0.28 | 0.32 | 0.32 | 0.33 | |
Operating CF/Net income |
2.43 | 0.79 | 1.68 | 1.36 | |
Capex/Depreciation |
(0.40) | (0.59) | (0.38) | (0.26) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
29.34% | 23.21% | 24.60% | 24.35% | |
Intangible Assets out of Total Assets |
0.85 | 0.82 | 0.82 | 0.82 | |
Share Based Compensation of Revenue |
1.50% | 0.94% | 0.97% | 0.64% | |
Graham Net Nets |
(0.96) | (0.41) | (0.42) | (0.37) | |
Graham Number |
57.11 | 58.76 | 57.23 | 58.31 | |
Earnings Yield |
7.59% | 6.65% | 6.18% | 6.51% | |
Free Cash Flow Yield |
10.49% | 8.58% | 9.05% | 8.35% | |
Revenue per Share |
5.60 | 5.81 | 5.92 | 5.59 | |
Operating CF per Share |
1.49 | 0.88 | 1.64 | 1.17 | |
Capex per Share |
(0.08) | (0.11) | (0.06) | (0.04) | |
Free Cash Flow per Share |
1.41 | 0.78 | 1.57 | 1.13 | |
Cash per Share |
1.88 | 1.32 | 1.30 | 2.43 | |
Shareholders Equity per Share |
40.38 | 38.95 | 38.21 | 37.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
40.38 | 38.95 | 38.21 | 37.23 | |
Free Cash Flow |
67.09 | 37.63 | 75.26 | 55.38 | |
Working Capital |
343.01 | 310.56 | 293.87 | 362.81 | |
Capital Expenditures |
(3.70) | (5.21) | (3.03) | (2.10) | |
Net Current Asset Value |
(2,155.04) | (1,175.31) | (1,231.86) | (1,119.90) | |
EV/EBIT |
14.44 | 12.38 | 12.26 | 11.94 | |
Capex to Sales |
0.01 | 0.02 | 0.01 | 0.01 | |
Net Profit Margin |
10.98% | 19.15% | 16.47% | 15.40% | |
Price to Operating Income |
7.73 | 9.28 | 9.16 | 9.22 | |
| Other line items | |||||
Average Receivables |
177.88 | 193.11 | 178.87 | 181.27 | |
Average Payables |
29.53 | 20.86 | 31.23 | 36.55 | |
Average Inventory |
171.67 | 153.42 | 157.56 | 157.61 | |
Average Assets |
4,000.10 | 3,448.27 | 3,412.12 | 3,379.58 | |
Average Common Equity |
1,886.10 | 1,861.21 | 1,808.94 | 1,778.37 |
Columns are period end dates